Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. - Wikidata - awgldk - TriplyDB

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

http://www.wikidata.org/entity/Q33374394

about

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Identifying prognostic features by bottom-up approach and correlating to drug repositioning Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.Cirrhosis and its complications: evidence based treatment.Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma.Systemic treatment of hepatocellular carcinoma: Past, present and future Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.Sorafenib: where do we go from here?Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.Systemic therapy in hepatocellular carcinoma.Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Novel inhibitors in development for hepatocellular carcinoma.Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.Developing better treatments in hepatocellular carcinoma.Gemox: a widely useful therapy against solid tumors-review and personal experience.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma.Treatment of intermediate-stage hepatocellular carcinoma.Hepatocellular carcinoma: systemic therapies and future perspectives.

P2860

Q28392783-512A28B9-6971-4118-963E-08233D8C3F20 Q28394414-0A55878C-4165-45AB-BF61-0F937B58C00A Q28543844-0C866FE8-5BE7-4FF8-BB9A-D28A7373C2B6 Q30479629-EEDDC983-A7DE-4968-B3D8-E9574CDB67A9 Q33376718-9DA93774-E102-41C4-8430-310F9CB0B1B9 Q33379418-D56A1965-992B-4FCF-81AF-CE7A7D500EB0 Q33395245-182D9697-ACDD-4F08-B431-2D3499DE1024 Q33397349-BF1AA8AD-307A-44A1-B4F3-E7A774F98E8A Q33400294-2729BF9A-0B3E-42F6-A4DD-9D0AFE7D7D37 Q33403870-47944CA2-35D8-4089-9186-A2BB77023983 Q33414726-1A3A1C32-657E-4E54-A6A4-8005095F4BFF Q33415172-BF1EC408-28B3-41EE-88E2-4E9F8E0B34CF Q33582751-8C04B055-5062-4F4F-A155-2CE208D209E2 Q33594931-B5F510F4-9249-4E9A-AB4F-9E046D2D92E3 Q33814048-1BC0836E-5DD3-4488-855F-08D29F7C6530 Q33854034-CA258630-93E4-437D-A0B8-C73BA6F0B1CD Q33920350-44E3EA09-4156-4F3B-9F18-AE78E08B4B26 Q34335251-65895DD3-4CF9-4C09-8AE3-05E823C2EB44 Q34458029-BA72EF31-CCF2-44D4-A266-8787B08C522D Q35421349-6977E323-9569-416F-8FF4-1B587F41D09D Q35535475-6CF31322-D4F9-4D62-8848-0FA887FA0CE5 Q35913461-FD5CB469-2929-430C-A4F9-5E636AF2C7CC Q36165081-0F2F061F-1F05-46D8-BEA2-F01455FEB2D3 Q36178201-A24FC48D-81B1-4558-88BB-5E1023AFBE02 Q36708741-4AED1537-01CE-421A-8D04-80B991A3C437 Q37049104-2EC5177F-E16E-4840-9808-60FCEC52A072 Q37050501-4B1F28B7-2467-4F4A-8FD7-2A5EBB6E259D Q37127099-45C31769-F9AD-45C0-9F2A-9D15BBDB565E Q37135733-FB05447E-FEF6-44AB-B7E1-173E4B9E0541 Q37700932-9EB1FED0-259F-4126-8FBF-E05FAE113E06 Q37724256-5E5DD49E-AC55-463F-8516-9782A32C93A3 Q37725994-F3F6A0A7-E008-42C3-92A8-D97C455DAEF5 Q37734197-F3BF35B8-CB6B-45EA-B5E3-7C6BD95922CF Q37798817-52F3E3B0-D623-4EA3-9EE1-D19956286357 Q37814700-40784A17-2496-4A5B-B74B-B1D2CC298F61 Q38073827-6FF3A8A7-EE23-41F5-A05A-8C86013C2C44 Q38160838-67B24320-BDD2-481A-B625-95F0B3271CDD Q38215428-2B910580-54B2-42F6-8887-6FEEF9365BF3 Q38236876-1A3A5359-AB7B-4D97-A6B7-B8BC71DE81EF Q38246965-F3B84F86-3545-470E-8F83-2C0DE8050937

P2860

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

http://www.wikidata.org/entity/Q33374394

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@ast

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@en

type

label

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@ast

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@en

prefLabel

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@ast

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@en

P1433

Q33374394-7294770B-E97B-4352-87FB-7593747E0B3E

P1476

Q33374394-F8D38EB5-636E-4396-8808-69F4FD17138A

P2093

Q33374394-1E35F0CF-7969-4035-9E1C-DF51F4DD755A

Q33374394-2AE895BF-ADBC-4D13-8DC9-B4F3DE793C4E

Q33374394-34B9EEB7-D841-4407-B736-04836D36A71C

Q33374394-7EF3260A-0E33-4629-B35F-92FF8D548B19

Q33374394-A445C8C4-898E-4A85-AEFB-3850F0728536

Q33374394-FD91F825-8FD7-45D9-AAA5-0116770B547B

P2860

Q33374394-6E91EC8D-7437-44C3-80F3-41AC159F48F1

Q33374394-8C0E48D8-64B9-4466-8378-B42D05E885A1

P304

Q33374394-F62A3363-7184-4F38-949B-192C9046BBED

P31

Q33374394-8EEE35C9-1375-4C73-9927-13A4415580D1

P356

Q33374394-C981C85A-8673-425F-801B-21D7EF44115D

P407

Q33374394-ED4AF48D-7BD8-43E2-8639-7503DFE4ECCA

P433

Q33374394-CEA43542-91FB-4998-BBC4-34FC76DB97F8

P478

Q33374394-02AAD0E4-748C-4E32-9494-C1088454B58A

P50

Q33374394-4ED79488-551C-41C5-B3E0-771F6B8AAF0D

Q33374394-7DEDC75D-BA1E-4FEB-9DA9-3F97F5FF59A7

Q33374394-C3E8ECA9-6B98-4FFF-8CCD-7E59E6C58143

Q33374394-CB86D3DE-C5A2-4F28-9A56-95B8673DAFC2

P577

Q33374394-0B34FFCC-D040-4DC2-A5ED-286F82366375

P5875

Q33374394-765928AF-3B87-4D59-9F02-F17BC4146029

P698

Q33374394-62A31E89-9743-4DAF-A382-A69091A6E0FD

P356

P1433

P1476

Gemcitabine plus oxaliplatin ( ...... : results of a phase II study.

@en

P2093

Amani Asnacios

http://www.w3.org/2001/XMLSchema#string

Luminita Bonyhay

http://www.w3.org/2001/XMLSchema#string

Michel Ducreux

http://www.w3.org/2001/XMLSchema#string

Samy Louafi

http://www.w3.org/2001/XMLSchema#string

Thierry de Baere

http://www.w3.org/2001/XMLSchema#string

Touraj Mansourbakht

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

P304

1384-1390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22532

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Poynard

Laurent Hannoun

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6475519

http://www.w3.org/2001/XMLSchema#string

P698

17330837

http://www.w3.org/2001/XMLSchema#string